Sleep-Disordered Breathing and Cardiac Arrhythmias in Adults — AHA Scientific Statement

Authors, Journal, Affiliations, Type, DOI

• Authors: Reena Mehra (Chair), Mina K. Chung (Vice Chair), Brian Olshansky, Dobromir Dobrev, Chandra L. Jackson, Vaishnavi Kundel, Dominik Linz, Nancy S. Redeker, Susan Redline, Prashanthan Sanders, Virend K. Somers; on behalf of the AHA Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology; and Stroke Council
• Journal: Circulation, 2022;146:e119–e136
• Affiliations: Cleveland Clinic Foundation (Mehra, Chung); University of Iowa (Olshansky); University Duisburg–Essen (Dobrev); NIH/NIEHS (Jackson); Icahn School of Medicine at Mount Sinai (Kundel); Maastricht University Medical Centre (Linz); Yale School of Nursing (Redeker); Brigham and Women's Hospital (Redline); University of Adelaide and Royal Adelaide Hospital (Sanders); Mayo Clinic (Somers)
• Type: AHA Scientific Statement (expert consensus; ≥80% agreement threshold; not formal clinical recommendations)
• DOI: https://doi.org/10.1161/CIR.0000000000001082

Overview

Sleep-disordered breathing (SDB) — encompassing obstructive sleep apnea (OSA), central sleep apnea (CSA), and Cheyne-Stokes breathing (CSB) — affects approximately 1 billion adults worldwide and is strongly implicated in cardiac arrhythmogenesis through autonomic fluctuations, intermittent hypoxia, intrathoracic pressure alterations, circadian dysregulation, and progressive structural cardiac remodeling. This statement synthesizes epidemiological, mechanistic, and interventional evidence across four arrhythmia subtypes: atrial fibrillation (primary focus), ventricular tachyarrhythmias, sudden cardiac death, and bradyarrhythmias. Observational data consistently support CPAP treatment reducing AF recurrence, but three randomized clinical trials have failed to confirm this benefit — a critical gap between biological plausibility and clinical evidence. The statement provides best-practice consensus statements, a stepped integrated clinical care model, and priority research gaps.

Keywords

Sleep-disordered breathing, obstructive sleep apnea, central sleep apnea, Cheyne-Stokes breathing, atrial fibrillation, ventricular tachyarrhythmia, sudden cardiac death, bradyarrhythmia, CPAP, autonomic nervous system, intermittent hypoxia, arrhythmogenesis, circadian rhythm

Key Takeaways

SDB Definitions

• OSA: Repetitive occlusion/narrowing of the upper airway; AHI ≥5/h with typical symptoms or AHI ≥15/h regardless of symptoms; daytime sleepiness poorly correlates with SDB severity in cardiac disease — unreliable as screening criterion in AF patients.
• CSA: Transient cessation of ventilatory effort by the pontomedullary respiratory pacemaker; results from CO₂ falling below the apneic threshold; defined as >50% of events classified as central.
• CSA–Cheyne-Stokes Breathing (CSB): Form of CSA in heart failure; heightened ventilatory chemosensitivity → alternating crescendo-decrescendo apneic and hyperpneic ventilatory periods. Bidirectional: delayed circulation time + poor LV function → CSA/CSB; SDB hypoxia + sympathetic activation → exacerbates cardiac dysfunction.
• SDB endotypes: Heterogeneous physiological contributors include low cortical arousal threshold, poor upper airway muscle responsiveness, elevated loop gain (ventilatory instability; common in HF → responds well to supplemental oxygen), and upper airway critical closing pressure. Personalized therapy direction based on endotyping is an emerging approach.
• In recumbency: rostral fluid redistribution → upper airway edema → obstructive events; pulmonary congestion → CO₂ below apneic threshold → central events; both can alternate in a single night.

Epidemiology and Shared Risk Factors

• SDB and AF share risk factors: increasing age, male sex, obesity.
• SDB-AF magnitude of association (HR 2.18) exceeds obesity-AF association (HR 1.49) — SDB may be a stronger AF driver than obesity.
• OSA contributes to hypertension through sympathetic nervous system excitation and vascular remodeling.
• Health inequities: Racial/ethnic groups facing marginalization have lower AF incidence but more symptomatic and persistent AF, less aggressive care, higher stroke risk and mortality. Black, Hispanic, and Chinese adults have higher prevalence of short sleep duration (an AF risk factor). Black individuals with SDB may have greater AF risk, possibly reflecting longer duration of untreated SDB.
• Racial differences in SDB endotypes (e.g. shorter apnea/hypopnea duration in Black women in MESA → low arousal threshold phenotype → poorer CPAP tolerability) may influence AF risk and treatment responsiveness.

AF: Epidemiology

• OSA prevalence in AF: 21–74% vs. 3–49% in controls; nearly 5-fold higher odds of AF with moderate-to-severe SDB after adjusting for obesity and cardiovascular risk.
• CSA and AF: CSA independently associated with 5.3–6.5 year excess AF risk; OR 3.00 (CSA in Sleep Heart Health Study), OR 2.58 (central apnea), OR 2.27 (CSB) in prospective cohorts.
• Nocturnal hypoxia (not AHI) predicted incident AF in 8,256 patients after controlling for confounders including pulmonary disease (HR 2.47 [95% CI 1.64–3.71]).
• VARIOSA-AF: Nights with highest SDB severity had 2× the likelihood of ≥1 hour of AF the following day vs. nights with lowest SDB severity; AF episodes did not predict respiratory events — SDB → AF directionality confirmed.
• Other sleep disturbances: Frequent nocturnal awakenings (33% ↑ AF risk over 11.6-year follow-up), insomnia (36% ↑ AF risk in 14 million California residents), shorter slow wave sleep (N3), lower sleep efficiency — all independently associated with AF. Healthy sleep composite (chronotype, duration, insomnia, snoring, daytime sleepiness) confers lower AF risk (HR 0.71 vs. unhealthy sleep, 11-year follow-up).

AF: Pathophysiology

• Autonomic NS: Each obstructive apnea → parasympathetic activation (diving reflex) → followed by sympathetic surge from hypoxia, arousal, and inhibition of pulmonary stretch → triggers and maintains AF. Ablation of right pulmonary vein ganglionated plexi, renal sympathetic denervation, and low-level vagosympathetic trunk stimulation all attenuate SDB-induced AF inducibility in animal models. CaMKII-dependent phosphorylation of sodium channels implicated.
• Intermittent hypoxia: AERP shortening → ↑AF inducibility; deoxygenation-reoxygenation → reactive oxygen species, vascular inflammation, blood pressure elevation.
• CO₂ fluctuations: Transition from hypercapnia to eucapnia → AERP return to baseline + persistent atrial conduction time prolongation → ↑AF vulnerability; hypocapnia in CSA-CSB → ↑electrical instability.
• Intrathoracic pressure: Mueller maneuver → postganglionic sympathetic nerve activity ↑>200%; intrathoracic pressure swings → transient AERP shortening + AF inducibility.
• Circadian rhythm: Central circadian clock affects cardiac electrophysiology; clock gene regulation of atrial K⁺ channels (Kv1.5 and Kv4.2); REM sleep timing regulated by circadian mechanisms — peak autonomic instability and most obstructive apneas during REM.
• Cardiac substrate remodeling: Connexin dysregulation → atrial conduction abnormalities; electrophysiological mapping during AF ablation in OSA → higher low-voltage areas, abnormal electrograms, increased atrial fibrosis, reduced conduction velocities; epicardial fat secretome → facilitates atrial substrate progression.

AF: Screening and Diagnosis

• NABS questionnaire (Neck circumference, Age, BMI, Snoring): AUC 0.82 for paroxysmal AF vs. STOP-BANG AUC 0.73 — validated, superior screening instrument for paroxysmal AF.
• Oxygen desaturation index (ODI) from overnight oximetry: AUC 0.95 for ruling out moderate-to-severe OSA (AHI ≥15) — accessible and validated in AF populations.
• No reliable CSA screening questionnaires available.
• HSAT validated in AF population against PSG — sufficient for diagnosing OSA in most AF patients without major comorbidities.
• In-lab polysomnography required for AF + HF (mixed/predominant CSA/CSB expected), pulmonary or neurological comorbidities, treatment-emergent CSA.
• High night-to-night AHI variability → repeat testing warranted if clinical suspicion persists despite initial negative test.
• Wearable devices using AI for simultaneous sleep and cardiac monitoring — emerging role; not yet standard.

AF: Treatment — CPAP Evidence

• Tracheostomy resolved nocturnal arrhythmias including AF in early historical studies.
• SDB present in 24–>50% of AF ablation candidates; associated with increased AF recurrence.
• CPAP — observational evidence:
  • Meta-analyses (n=1,087–4,516): 42–44% reduction in AF recurrence with CPAP; 57% increased AF recurrence risk with untreated OSA vs. non-OSA.
  • CPAP-treated OSA → AF recurrence rates similar to non-OSA patients.
  • CPAP reduced AF progression to permanent AF in 10,132-patient registry (HR 0.66 [95% CI 0.46–0.94]).
  • Benefits most pronounced in younger, obese, and male patients (meta-regression).
• CPAP — RCT evidence (all non-significant for primary AF outcomes):
  • SAVE (n=2,717, 3.7y): No AF reduction in composite cardiovascular outcome; CPAP improved only daytime sleepiness, snoring, mood, and QoL.
  • Caples (n=25, ≤1y): No difference in AF recurrence; severely underpowered; 12-lead ECG monitoring only.
  • Traaen (n=579, 5 mo): CPAP in paroxysmal AF + SA → no significant AF burden reduction; AF burden lower than anticipated (5.6%→4.1% CPAP; 5.0%→4.3% control); study underpowered.
• ARREST-AF and LEGACY: Aggressive multifactorial risk factor reduction (OSA + weight management + lifestyle) significantly reduced AF burden after catheter ablation.
• Conclusion: Compelling mechanistic and observational data support OSA treatment in AF, but definitive RCT evidence is lacking; recommendation is for SDB treatment as part of lifestyle modification — not as isolated intervention.

AF: 2022 AHA Best Practice Consensus Statements

• Screen for OSA in AF, particularly in patients with obesity, hypertension, or predominant nocturnal AF episodes.
• Daytime sleepiness has limited utility for AF-specific OSA screening.
• In-lab PSG preferred for AF + HF (CSA predominant), pulmonary hypertension, or neurological comorbidities.
• SDB management as part of multidisciplinary integrated lifestyle modification with shared decision-making.
• SDB treatment as part of lifestyle modification to reduce AF risk, prevent progression, and improve patient-reported outcomes.

VTAs and Sudden Cardiac Death

• Epidemiology: 2-fold higher odds of NSVT; 50% higher odds of complex ventricular ectopy in SDB.
• Longitudinal cohort (n=10,701, 5.3y): SCD independently predicted by AHI >20 (HR 1.60), mean nocturnal O₂ sat <93% (HR 2.93), nadir O₂ sat <78% (HR 2.60); all P<0.0001.
• Nocturnal SCD predilection: SCD from midnight to 6AM in OSA patients has relative risk 2.57 (95% CI 1.87–3.52) vs. non-OSA patients; non-OSA SCD distributed uniformly throughout the day.
• In CSA/CSB: ventricular ectopy increases during the hyperpneic phase (chemostimulation, BP, HR at peak) rather than apneic phase.
• SERVE-HF: Higher CSB (>20% recording time) → higher VTA frequency (>30 PVCs/h) in HFrEF (LVEF ≤45%); however, ASV-related increased cardiovascular death limits this therapy.
• Pathophysiology: Impaired baroreflex → ↑sympathetic/↓parasympathetic → VTA/SCD; hypoxia + acidosis → EADs + triggered activity; acute upper airway obstruction → dynamic QT prolongation → electromechanical window shortening → ↑ventricular ectopy; KLF15 deficiency → loss of rhythmic QT variation → ↑VTA/SCD.
• ESC guideline: Class IIb — SDB and hypoxia may be considered a risk factor for SCD; include OSA in SCD risk stratification.

Bradyarrhythmias

• Most common cardiac arrhythmias during sleep in SDB: sinus bradycardia, sinus pauses, 1st- and Mobitz I 2nd-degree AV block.
• Prevalence: Nocturnal sinus bradycardia 7.2–40%; 2nd/3rd degree AV block 1.3–13.3%; sinus pauses 3.3–33%.
• AHI-severity threshold for heart block: none at AHI <60/h; 17/97 (17.5%) at AHI ≥60/h.
• High prevalence of undiagnosed SDB in pacemaker patients.
• Pathophysiology: Prolonged apneas + hypoxia → enhanced parasympathetic tone (most marked during REM) → vagotonic hypoxic stimulation of carotid body → bradycardia; susceptibility varies by inherent hypoxic chemosensitivity and sinoatrial node responsiveness.
• CPAP eliminated AV block in 12/17 patients; reduced bradycardic events in larger cohorts.
• ACC/AHA/HRS Guideline:
  • Class I COR, LOE B-NR: Screen for SDB in documented/suspected sleep-related bradycardia or conduction disorder.
  • Class I COR, LOE B-NR: Treat SDB in patients with sleep-related bradycardia/conduction disorder and documented OSA.
  • Class IIa COR, LOE B-NR: Screen for SDB in patients receiving/considered for permanent pacemaker.
  • Class III COR, LOE C-LD: Do not pace for sleep-related sinus bradycardia/pauses unless other indications exist.
• AHA 2022 Consensus: Assess for SDB before pacemaker placement when feasible for profound nocturnal bradyarrhythmia.

Integrated Clinical Care Model

• Stepped care framework: (1) Guideline-directed therapy, (2) SDB screening, (3) SDB diagnostics as indicated, (4) SDB treatment as indicated, (5) Arrhythmia risk factor + SDB management with follow-up, (6) Teaching and self-care support.
• Requires electrophysiologist–sleep medicine interdisciplinary collaboration; patient-centric shared decision-making; technology support (anticoagulation, rate/rhythm control, lifestyle modification).

Limitations of the Document

• Most existing data are observational; only 3 small-to-moderate RCTs of CPAP for AF — all non-significant, limited by sample size, monitoring quality, lower-than-anticipated AF burden, and short follow-up.
• Bidirectional SDB–cardiac disease associations complicate causal inference.
• Predominant focus on SDB and AF; VTA/bradyarrhythmia evidence base substantially thinner.
• Limited CSA screening tools; CSA-specific treatment for arrhythmias largely unstudied.
• Racial/ethnic health equity data incomplete; SDB endotype data in diverse populations limited.
• High night-to-night AHI variability limits single-night assessments.

Key Concepts Mentioned

• concepts/Sleep-Disordered-Breathing — primary topic; OSA/CSA/CSB definitions, endotypes, diagnostic framework
• concepts/OSA-Arrhythmogenic-Substrate — extended mechanistic framework; circadian, VTA, bradyarrhythmia additions
• concepts/Catheter-Ablation-AF — OSA increases AF recurrence post-PVI; CPAP observational benefit
• concepts/AF-CARE — SDB management as comorbidity pillar
• concepts/Sudden-Cardiac-Death — OSA as SCD risk factor; nocturnal SCD predilection
• concepts/Drug-Induced-Arrhythmia — KLF15 and circadian QT variation; EAD-mediated VTA mechanism overlap

Key Entities Mentioned

• entities/Obstructive-Sleep-Apnea — updated epidemiology, VTA/SCD/bradyarrhythmia sections, new screening tools, RCT evidence
• entities/Atrial-Fibrillation — SDB as major risk factor; VARIOSA-AF study; CPAP RCT evidence
• entities/Heart-Failure — CSA/CSB in HF; SERVE-HF; bidirectional HF–CSA relationship

Wiki Pages Updated

• Created: wiki/sources/sdb-arrhythmia-aha-2022.md
• Created: wiki/concepts/Sleep-Disordered-Breathing.md
• Updated: wiki/concepts/OSA-Arrhythmogenic-Substrate.md
• Updated: wiki/entities/Obstructive-Sleep-Apnea.md
• Updated: wiki/entities/Atrial-Fibrillation.md
• Updated: wiki/sourceindex.md
• Updated: wiki/wikiindex.md